CLDN18.2 CAR-T cells / Innovative Cellular Therapeutics - LARVOL DELTA

Novel Antibody-Drug Conjugate Shows Potential in Treating CLDN18.2-Positive Gastric and GEJ Cancers (THE ASCO POST) - "Commenting on the study findings, ASCO Expert in gastrointestinal cancers Pamela Kunz, MD...said: 'The recent phase III SPOTLIGHT and GLOW studies put CLDN18.2 on the map as a viable target for gastroesophageal cancer. It is one of the most exciting new targets for patients with advanced gastroesophageal cancer....CMG901 represents a new way to interrogate this target. What's exciting for patients is the potential for an entirely new class of therapies for advanced gastroesophageal cancer-we will all eagerly await future studies.'"

Media quote